Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326183 | 0.91 | RAB9A (0.50) | RAB9ASMN1; SMN2NPC1CYP2C19MEN1 | |
| SCHEMBL6858339 | 0.90 | CTSD (0.46) | RAB9ASMN1; SMN2NPC1CYP2C19MEN1 | |
| SCHEMBL29052118 | 0.90 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1CYP2C19MEN1 | |
| SCHEMBL4406336 | 0.89 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1CYP2C19MEN1 | |
| SCHEMBL4668525 | 0.87 | HTR2A (0.48) | RAB9ASMN1; SMN2NPC1CYP2C19MEN1 | |
| SCHEMBL13246821 | 0.86 | CYP3A4 (0.52) | RAB9ASMN1; SMN2NPC1CYP2C19MEN1 | |
| SCHEMBL14514229 | 0.85 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1CYP2C19MEN1 | |
| SCHEMBL31539516 | 0.84 | ALDH1A1 (0.55) | RAB9ASMN1; SMN2NPC1CYP2C19MEN1 | |
| SCHEMBL29976361 | 0.84 | RAB9A (0.57) | RAB9ASMN1; SMN2NPC1CYP2C19MEN1 | |
| SCHEMBL67755 | 0.84 | RAB9A (0.57) | RAB9ASMN1; SMN2NPC1CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12324769-B1 | Double-network versatile hydrogel with antibacterial and drug sequential release capabilities | EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIVERSITY (CN) | 2025-06-10 | — | — | US | claimed |
| US-20250169985-A1 | DOUBLE-NETWORK VERSATILE HYDROGEL WITH ANTIBACTERIAL AND DRUG SEQUENTIAL RELEASE CAPABILITIES | EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIVERSITY (CN) | 2025-05-29 | — | — | US | claimed |
| CN-119570065-A | Composite hydrogel precursor liquid, preparation method and application thereof, and preparation method of anti-swelling medical hydrogel | 南通大学 | 2025-03-07 | — | — | CN | claimed |
| CN-117482289-B | Preparation method of double-network multifunctional hydrogel with antibacterial and drug sequential release capabilities | 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) | 2024-05-28 | — | — | CN | claimed |
| CN-117482289-A | Preparation method of double-network multifunctional hydrogel with antibacterial and drug sequential release capabilities | 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) | 2024-02-02 | — | — | CN | claimed |
| CN-115895280-B | Photosensitive silk fibroin hydrogel and preparation method and application thereof | 南通大学 | 2024-01-26 | — | — | CN | claimed |
| CN-115895280-A | Photosensitive silk fibroin hydrogel and preparation method and application thereof | 南通大学 | 2023-04-04 | — | — | CN | claimed |
| CN-115710776-A | Antibacterial hemostatic adhesive film for activating immunoreaction by illumination, preparation method and application | 南通大学 | 2023-02-24 | — | — | CN | claimed |
| US-7166696-B2 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-01-23 | — | — | US | claimed |
| US-20040265899-A1 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-30 | — | — | US | claimed |
| EP-1373167-A2 | SOLID PHASE SYNTHESIS SUPPORTS AND METHODS | 3M Innovative Properties Company (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020173051-A1 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | claimed |
| WO-2002081078-A2 | SOLID PHASE SYNTHESIS SUPPORTS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-10-17 | — | — | WO | claimed |
| CN-120242011-A | Preparation method of HIV blocking nano-particles for targeting and activating immune cells | 南通大学 | 2025-07-04 | — | — | CN | disclosed |
| US-12324769-B1 | Double-network versatile hydrogel with antibacterial and drug sequential release capabilities | EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIVERSITY (CN) | 2025-06-10 | — | — | US | disclosed |
| US-20250169985-A1 | DOUBLE-NETWORK VERSATILE HYDROGEL WITH ANTIBACTERIAL AND DRUG SEQUENTIAL RELEASE CAPABILITIES | EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIVERSITY (CN) | 2025-05-29 | — | — | US | disclosed |
| US-20030228619-A1 | Peptide nucleic acids as tags in encoded libraries | XENOPORT, INC. | 2003-12-11 | — | — | US | disclosed |
| EP-1360004-A1 | CATALYSTS | Johnson Matthey PLC (GB) | 2003-11-12 | — | — | EP | disclosed |
| US-20020173051-A1 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002066159-A1 | CATALYSTS | JOHNSON MATTHEY PLC (GB) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173051-A1 | Solid phase synthesis supports and methods | FES, LSS, CCNK | RAB9A 4289/4885SMN1; SMN2 1357/4885NPC1 2024/4885 |
| US-20040265899-A1 | Solid phase synthesis supports and methods | FES, LSS, CCNK | RAB9A 4289/4885SMN1; SMN2 1357/4885NPC1 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.